Iroxanadine [203805-20-3]
Cat# T27627-5mg
Size : 5mg
Brand : TargetMol
Iroxanadine
(Synonyms: BRX-235, BRX235, BRX-005, BRX005, BRX 235, BRX 005) Copy Product InfoIroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5
Select Batch
Purity:99.04%
Appearance:Solid
Color:White to Yellow
COA HPLC HNMR
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5 |
| In vivo | Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.[1] |
| Synonyms | BRX-235, BRX235, BRX-005, BRX005, BRX 235, BRX 005 |
| Molecular Weight | 260.33 |
| Formula | C14H20N4O |
| Cas No. | 203805-20-3 |
| Smiles | C(C1NC(=NOC1)C=2C=CC=NC2)N3CCCCC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (172.86 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||




